) and is currently not widely available. Management of rifampicin-resistant TB now involves a 6month all-oral regimen for most patients, including PWH. While significant gains have recently been made toward decreasing mortality from HIV-associated TB, there are many ongoing challenges, some of which are being addressed in active clinical trials.
Meintjes et al. (Mon,) studied this question.